Rocket Pharmaceuticals, Inc.(RCKT) Stock Research - Grey Stern Research
Loading...

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis

$22.62 (-3.33%)

RCKT Financial Performance


Use the table below to view Rocket Pharmaceuticals, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q4 - 2023

Metric Value Ranking among Peers
Price $23.40 -
52 Week Low $14.89 -
52 Week High $32.53 -
Market Cap $2.1 Billion 7/21
Gross Margin 50% 7/21
Profit Margin -100% 9/21
EBITDA margin -710% 11/21
Q4 - 2023 Revenue $10.3 Million 5/21
Q4 - 2023 Earnings -$63.1 Million 14/21
Q4 - 2023 Free Cash Flow -$34.0 Million 10/21
Trailing 4 Quarters Revenue $10.3 Million 9/21
Trailing 4 Quarters Earnings -$245.6 Million 16/21
Quarterly Earnings Growth 2% 6/21
Annual Earnings Growth -3% 5/21
Quarterly Revenue Growth 0% 6/21
Annual Revenue Growth 0% 6/21
Cash On Hand $55.9 Million 19/21
Short Term Debt $2.7 Million 10/21
Long Term Debt $22.3 Million 11/21

Rocket Pharmaceuticals, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Rocket Pharmaceuticals, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 1/21
PS 206.00 7/21
PB 4.31 8/21
PC 38.00 4/21
Liabilities to Equity 0.15 12/21
ROA -0.43 12/21
ROE -0.50 8/21
Current Ratio 7.68 8/21
Quick Ratio 0.76 17/21
Long Term Debt to Equity 0.05 9/21
Debt to Equity 0.05 9/21
Burn Rate 0.87 16/21
Cash to Cap 0.03 18/21
CCR 0.54 13/21
EV to EBITDA -28.58 15/21
EV to Revenue 203.01 7/21

Company Details

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

CEO: Dr. Gaurav Shah

Website: https://rocketpharma.com

Address: 350 5th Ave Ste 7530 New York City, NEW YORK

Exchange: NASDAQ Global Market

Industry: Biotechnology

Rocket Pharmaceuticals, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Rocket Pharmaceuticals, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Dyne Therapeutics, Inc. DYN $2.2 Billion
Solid Biosciences Inc. SLDB $343.5 Million
uniQure N.V. QURE $243.2 Million
Syndax Pharmaceuticals, Inc. SNDX $1.7 Billion
Cytokinetics, Incorporated CYTK $6.2 Billion
REGENXBIO Inc. RGNX $787.6 Million
Merus N.V. MRUS $2.6 Billion
Rhythm Pharmaceuticals, Inc. RYTM $2.3 Billion
MeiraGTx Holdings plc MGTX $367.2 Million
Mirum Pharmaceuticals, Inc. MIRM $1.1 Billion
Replimune Group, Inc. REPL $395.3 Million
Stoke Therapeutics, Inc. STOK $724.5 Million
Sutro Biopharma, Inc. STRO $328.0 Million
Revolution Medicines, Inc. RVMD $6.5 Billion
Larimar Therapeutics, Inc. LRMR $470.8 Million
Pliant Therapeutics, Inc. PLRX $921.2 Million
Vaxcyte, Inc. PCVX $8.1 Billion
Inozyme Pharma, Inc. INZY $284.5 Million
Viridian Therapeutics, Inc. VRDN $858.4 Million
Day One Biopharmaceuticals, Inc. DAWN $1.4 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
RCKT Income Statements
Quarter Year Revenue Earnings
Q4 2023 $ 10.3 Million -$63.1 Million
Q3 2023 $ 0 -$61.9 Million
Q2 2023 $ 0 -$65.7 Million
Q1 2023 $ 0 -$54.9 Million
Q4 2022 $ 0 -$64.4 Million
Q3 2022 $ 0 -$57.8 Million
Q2 2022 $ 0 -$54.4 Million
Q1 2022 $ 0 -$43.0 Million

View All

RCKT Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2023 $55.9 Million $566.3 Million $25.0 Million $492.6 Million
Q3 2023 $225.7 Million $598.8 Million $25.2 Million $541.1 Million
Q2 2023 $45.1 Million $461.8 Million $25.4 Million $403.0 Million
Q1 2023 $64.6 Million $514.8 Million $25.4 Million $458.9 Million
Q4 2022 $140.5 Million $551.8 Million $22.9 Million $489.7 Million
Q3 2022 $196.7 Million $417.3 Million $22.1 Million $367.3 Million
Q2 2022 $187.5 Million $431.9 Million $22.3 Million $387.7 Million
Q1 2022 $130.6 Million $460.2 Million $22.4 Million $417.6 Million

View All

RCKT Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q4 2023 -$34.0 Million -$4.6 Million -$169.8 Million
Q3 2023 -$61.8 Million -$4.7 Million $180.6 Million
Q2 2023 -$55.0 Million -$4.1 Million -$19.5 Million
Q1 2023 -$60.6 Million -$3.0 Million -$75.9 Million
Q4 2022 -$59.3 Million -$3.3 Million -$56.2 Million
Q3 2022 -$121.9 Million $177,000 $9.1 Million
Q2 2022 -$78.1 Million $177,000 $57.0 Million
Q1 2022 -$41.2 Million -$2.0 Million -$102.1 Million

View All